SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
biotech firesales
An SI Board Since August 2001
Posts SubjectMarks Bans
3661 167 0
Emcee:  dalroi Type:  Moderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2686AZN's Brilinta is a different drug class from Lovenox (it's an antiplateDewDiligence_on_SI-7/27/2010
2685Perhaps another FDA report on Monday accounted for some of today's loss... Ian@SI-7/27/2010
2684<i>>…it's clear from the commentators on your iH thread that the baDewDiligence_on_SI-7/27/2010
2683My problem with that explanation is that it's clear from the commentators ontom pope-7/27/2010
2682<i>>Momenta (MNTA) off 15% now. Not sure if it's the lawsuit filed DewDiligence_on_SI-7/27/2010
2681Momenta (MNTA) off 15% now. Not sure if it's the lawsuit filed by Sanofi --tuck-7/27/2010
2680Vivus Confident In Obesity Drug Despite FDA Panel Rejection Date : 07/15/2010 @mlkr-7/16/2010
2679Northwest Biother -20% ($0.26) to $1.10 Yesterday based on a "piece" John McCarthy27/16/2010
2678VVUS failure: off 62% to 4.5 Strike one. Vivus’s Qnexa, the first of three newRockyBalboa17/15/2010
2677NEXMD (as adjusted for a 1-for-15 reverse split of the Issuer's common stockmlkr-7/8/2010
2676NexMed, (NEXMD), today announced continued listing with NASDAQ, but is nevertheltuck-7/7/2010
2675Their restructuring focused on the following after recent setback for Horizant tmlkr-7/7/2010
2674AFFX $4.00s now:8:26AM Affymetrix lowers Q2 rev guidance below consensus (AFFX)mlkr-7/7/2010
2673AFFX down 25% on bad 2nd Q.Rocky9-7/7/2010
2672XNPT $6.00 now on following news: GlaxoSmithKline: No Improvement For GSK1838262mlkr-7/7/2010
2671Oldtimer XNPT fail mid-stage trial, crashes... -33% to 6 again. BRIEF-Glaxo, XeRockyBalboa-7/7/2010
2670I hear you. And yet many patients opt for palliative treatment given the overallRockyBalboa-7/2/2010
2669MIPI spiked recently, today it gets clobbered on BK warning BRIEF-Molecular InsRockyBalboa-7/2/2010
2668How much is a month of life worth if the QOL doesn't completely suck? Thereoldirtybastard17/1/2010
2667the whole approval is a sad joke. Patients here just shake their heads on mere 4RockyBalboa-7/1/2010
2666AFFY ; Dropped to $5.89 with shorties' daring bets in down markets and then mlkr-7/1/2010
2665one question is whether it has, as stated in a previous PR, already received a toldirtybastard-6/30/2010
266452 week high was $57 - just traded into high $24's. DaveDave O.-6/30/2010
2663More on DNDN: cms.gov;RockyBalboa-6/30/2010
2662DNDN trading in mid $26's - was as low as $25 AH today down from yesterday&#Dave O.-6/30/2010
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News